TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37535953
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (no HBV treatment)
Study: 37535953
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (single HBV treatment)
Study: 37535953
Drug: Group 3
Normalized name: Chlamydophila psittaci biogroup 3 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3 (dual HBV treatment)
Study: 37536936
Drug: TLPLDC+G (n=56)
Normalized name: N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLPLDC+G (n=56)
Study: 37536941
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg every 2 weeks for a total of 17 doses) and ipilimumab (1 mg/kg every 6 weeks for a total of 6 doses) starting 2 weeks prior to radiotherapy
Study: 39639088
Drug: Afatinib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (40 mg daily)
Study: 37537548
Drug: Two distinct
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two distinct approaches to involving parents in adolescent obesity treatment
Study: 37537580
Drug: Low-molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular weight heparin (LMWH) alone
Study: 37537580
Drug: LMWH and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH and aspirin
Study: 37538173
Drug: Brensocatib (QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brensocatib (QD dosing)
Study: 37538539
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of 125 μg subcutaneous pegylated IFNβ-1a
Study: 37538951
Drug: Colistin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin monotherapy (5 mg/kg once followed by 1.67 mg/kg every 8 hours)
Study: 37538951
Drug: Colistin in
Normalized name: colistin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin in combination with meropenem (1000 mg every 8 hours)
Study: 37540036
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) added to furosemide, eGFR-adjusted doses
Study: 37540566
Drug: One or
Normalized name: Geone Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: One or two infusions of third-generation CD19-directed CAR-Ts (2 × 10^8/m2)
Study: 37540593
Drug: Thyroid hormones
Normalized name: Thyroid hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormones (TSH, T3, T4) and sex hormones (PRL, total testosterone) measured preoperatively and at 24 h postoperatively
Study: 37540921
Drug: CCRT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCRT plus TIL infusion (n = 78)
Study: 37541263
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (randomised pathway)
Study: 37541263
Drug: Non-surgical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical treatment (randomised pathway)
Study: 37541263
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (patient choice pathway)
Study: 37541263
Drug: Non-surgical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical treatment (patient choice pathway)
Study: 37541273
Drug: Erdafitinib (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdafitinib (8 mg/day, with potential up-titration to 9 mg/day)
Study: 37541600
Drug: Abstinence-Contingent Wage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abstinence-Contingent Wage Supplement
Study: 37541683
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of ropivacaine 0.2% 4-8 mL/hour
Study: 37541683
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of ropivacaine 0.5%, 20 mL
Study: 37541705
Drug: Dispersible and
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible and immediate-release FDC abacavir (60 mg or 600 mg), dolutegravir (5 mg or 50 mg), and lamivudine (30 mg or 300 mg) tablets taken once per day.
Study: 37541921
Drug: 3.36 g
Normalized name: IODINE 33.36 g in 1 L TOPICAL SOLUTION [NU-OPT 330]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.36 g eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) daily for 30 months
Study: 37541951
Drug: Ketamine (subanaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (subanaesthetic doses, blood concentration of 0.2-0.3 μg ml)
Study: 37542222
Drug: GMB/GMB group
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMB/GMB group (galcanezumab 120 mg)
Study: 37542222
Drug: PBO/GMB group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBO/GMB group (placebo followed by galcanezumab 240 mg loading dose and then two 120 mg doses)
Study: 37542234
Drug: Exercise snacking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise snacking intervention (twice daily for 28 days, consisting of five muscle-strengthening exercises)
Study: 37542331
Drug: Breakfast Task
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Breakfast Task training (5 sessions, 45 minutes each, delivered online, twice a week)
Study: 37542470
Drug: Lanreotide (LAN)
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanreotide (LAN) treatment initiation
Study: 37542470
Drug: Lanreotide (LAN)
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanreotide (LAN) treatment
Study: 37542674
Drug: Mini-oral sulfate
Normalized name: oxymetazoline hydrochloride Nasal Solution [Iliadin Mini]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-oral sulfate tablet (mini-OST)
Study: 37542674
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral sulfate tablet (OST)
Study: 37543437
Drug: Conventional oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oxygen treatment with a Venturi mask
Study: 37543575
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus paravertebral block (ropivacaine 0.5% loading, 0.2% infusion)
Study: 37543590
Drug: Tablet without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet without the PREVEDEL software (Control group)
Study: 37543602
Drug: MRI scan,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI scan, neuropsychological tests, ophthalmic examination
Study: 37544143
Drug: Triple antithrombotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antithrombotic treatment consisting of subcutaneous enoxaparin, VKA, and discontinued aspirin
Study: 37544326
Drug: cAd3-EBO S
Normalized name: TPG-S
DrugBank: Tocofersolan (DB11635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cAd3-EBO S vaccine at 1 × 10^11 viral particles
Study: 37544326
Drug: cAd3-EBO S
Normalized name: TPG-S
DrugBank: Tocofersolan (DB11635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cAd3-EBO S vaccine at 1 × 10^10 viral particles
Study: 37544492
Drug: Urine chemistry-guided
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urine chemistry-guided diuretic strategy
Study: 37545290
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CYFRA 21-1 and CA 125 biomarkers
Study: 37545298
Drug: Intermittent low-carbohydrate
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent low-carbohydrate diet (ILCD) - carbohydrate intake ≤ 50 g/d on seven nonconsecutive days
Study: 37545392
Drug: CAP-100 (anti-CCR7
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAP-100 (anti-CCR7 antibody)
Study: 37545406
Drug: Lacosamide (LCM)
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lacosamide (LCM) up to 12 mg/kg/day or 600 mg/day
Study: 37545580
Drug: Delayed oral
Normalized name: lipase 12,000 UNT / amylase 39,000 UNT / protease 39,000 UNT Delayed Oral Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed oral feeding (DOF)
Study: 38466872
Drug: VR neuroscience-based
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VR neuroscience-based therapy (VRNT)
Study: 37547448
Drug: Posttreatment residual
Normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posttreatment residual tumors in the breast and lymph nodes after neoadjuvant chemotherapy
Study: 37547664
Drug: Gonadotoxic childhood
Normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotoxic childhood therapy
Study: 37548010
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis for acute stroke in the prehospital setting
Study: 37548555
Drug: UGN-102 once
Approvals — FDA: no, EMA: no, PMDA: no
Description: UGN-102 once weekly for 6 weeks
Study: 37548555
Drug: Transurethral resection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transurethral resection of bladder tumor monotherapy
Study: 37548831
Drug: Chemotherapy (n=77)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (n=77)
Study: 37548850
Drug: Intravenous bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous bevacizumab (IA BEV)
Study: 37549351
Drug: Acromegaly treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acromegaly treatment
Study: 37549598
Drug: LCPUFA-ω3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCPUFA-ω3 supplementation (225 mg DHA, 45 mg EPA, administered at 0.100 g/kg of body weight/day for 3 months)
Study: 37549598
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (500 mg sunflower oil)
Study: 37549675
Drug: PFCs as
Approvals — FDA: no, EMA: no, PMDA: no
Description: PFCs as adjunct in cancer therapies
Study: 37549680
Drug: BNT162b2 (third
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 (third dose)
Study: 37549724
Drug: Bedside family
Normalized name: Bedside-Care
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bedside family planning counseling and offer of contraception (oral contraceptive pills, etonogestrel implant, or medroxyprogesterone injection)
Study: 37549933
Drug: Dexamethasone 0.5 mg/5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.5 mg/5 mL in Mucolox™
Study: 37549933
Drug: Dexamethasone 0.5 mg/5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.5 mg/5 mL solution (standard arm)
Study: 37550019
Drug: Single-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose oral secnidazole 2 g
Study: 37550157
Drug: Elevated serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated serum alkaline phosphatase (ALP) quartile Q4 (ALP >83.00 U/L)
Study: 37550429
Drug: Blinatumomab (immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinatumomab (immunotherapy drug)
Study: 37550730
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care followed by delayed treatment with TranS-C (UC-DT)
Study: 37551324
Drug: Active surveillance
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active surveillance (weekly)
Study: 37551324
Drug: Immunoglobulin G
Normalized name: immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulin G positivity
Study: 37551412
Drug: 150 min/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 min/wk of moderate-intensity aerobic, resistance, or combination exercise
Study: 37551532
Drug: Drug-Eluting Balloon
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Eluting Balloon (DEB) angioplasty (SEQUENT PLEASE)
Study: 37551532
Drug: Drug-Eluting Stent
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Eluting Stent (DES) (Promus Premier and Promus Elite)
Study: 37551550
Drug: Labisia pumila
Normalized name: Ulmus pumila pollen
DrugBank: Ulmus pumila pollen (DB10362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labisia pumila standardized extract (SKF7®) 750 mg
Study: 37551841
Drug: Fibrin-based haemostatic
Normalized name: Fibrin-based agent containing a N-terminally modified parathyroid hormone fragment TGplPTH1-34
DrugBank: KUR-113 (DB18413)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin-based haemostatic agents (FBHAs)
Study: 37552083
Drug: Therapies reported
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapies reported
Study: 37552303
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg/d (n=150)
Study: 37552330
Drug: Vitamin K4
Normalized name: Vitamin K4
DrugBank: Acetomenaphthone (DB19387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K4 (1 mg) for 24 weeks
Study: 37552407
Drug: Telmisartan (10-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (10-80 mg daily)
Study: 37552407
Drug: Enalapril (5-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5-40 mg daily)
Study: 37553338
Drug: inactivated SARS-CoV-2
Normalized name: Inactivated SARS-Cov-2 Vaccine
DrugBank: Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences) (DB15863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: inactivated SARS-CoV-2 vaccine
Study: 37553488
Drug: MRI-guided focused
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI-guided focused ultrasound (MRgFUS) treatment
Study: 37554078
Drug: Insulin-controlled euglycemia
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-controlled euglycemia (control)
Study: 37554078
Drug: Total insulin
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total insulin withdrawal for 14 hours
Study: 37554125
Drug: Sintilimab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab (200 mg, day 1) plus bevacizumab (7.5 mg/kg, day 1), oxaliplatin (135 mg/m2, day 1), and capecitabine as first-line therapy
Study: 37554510
Drug: Intravenous reinduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous reinduction of Ustekinumab (UST) followed by subcutaneous q8w or q4w
Study: 37555284
Drug: Entinostat 2
Normalized name: entinostat
DrugBank: Entinostat (DB11841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entinostat 2 mg orally weekly in combination with standard dose carboplatin, etoposide, and atezolizumab
Study: 37555345
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention (PCI) plus optimal medical and device therapy (OMT)
Study: 37555345
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical and device therapy (OMT) alone
Study: 37555595
Drug: Low-dose ato-oxy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ato-oxy (0.5 mg/kg atomoxetine and 5 mg oxybutynin)
Study: 37555595
Drug: High-dose ato-oxy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ato-oxy (1.2 mg/kg atomoxetine and 5 mg oxybutynin)
Study: 37556515
Drug: Tildrakizumab 100
Normalized name: tildrakizumab 100 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tildrakizumab 100 mg subcutaneously at week 0, week 4, and every 12 weeks thereafter
Study: 37556515
Drug: Tildrakizumab 100
Normalized name: tildrakizumab 100 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tildrakizumab 100 mg subcutaneously
Study: 37556775
Drug: Palbociclib +
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib + Endocrine Therapy (ET)
Study: 37556856
Drug: Plyometric high-intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plyometric high-intensity interval training (PLYO), 8 weeks, twice weekly
Study: 37556856
Drug: Cycle-oriented high-intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle-oriented high-intensity interval training (CYC), 8 weeks, twice weekly
Study: 37556913
Drug: BI 894999
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 894999 (Schedule A: 0.2, 0.5, 1.0, 1.5, 2.0, and 5.0 mg, Days 1-21/21-d cycle)
Study: 37556913
Drug: BI 894999
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 894999 (Schedule B: 1.5, 2.0, and 2.5 mg, Days 1-15/21-d cycle)
Study: 37556913
Drug: BI 894999
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 894999 (Schedule C: loading dose 5.0, 6.0, or 7.0 mg on Day 1 followed by maintenance dose 2.5, 3.0, or 3.5 mg, Days 2-7 and 15-21/28-d cycle)
Study: 37558400
Drug: Disease-modulating therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease-modulating therapy (DMT)
Study: 37559023
Drug: Standard adequate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard adequate haemodialysis with a dialysate potassium concentration of 2.0 mmol/L
Study: 37559050
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg per day for 21 days every 28 days
Study: 37559530
Drug: Caffeine therapy
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine therapy (n = 12)
Study: 37559530
Drug: No caffeine
Normalized name: caffeine Oral Tablet [No Doz]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No caffeine therapy (n = 16)
Study: 37559753
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg lufotrelvir (SAD)
Study: 37559753
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg lufotrelvir (SAD)
Study: 37559753
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg lufotrelvir (MAD)
Study: 37559753
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg lufotrelvir (MAD)
Study: 37560813
Drug: Immunochemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunochemotherapy with dose reduction in patients ≤55 years old after achieving complete metabolic response (CMR)
Study: 37560813
Drug: Immunochemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunochemotherapy with standard dose (BURKIMAB08 trial)
Study: 37561249
Drug: Orbital radiotherapy
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orbital radiotherapy (OR) with a total dose of 20 Gy, divided into 10 sessions of 2 Gy each, with concomitant oral intake of low-dose glucocorticoids.
Study: 37561451
Drug: Pertuzumab plus
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab plus trastuzumab without chemotherapy (group A)
Study: 37561451
Drug: Pertuzumab plus
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab plus trastuzumab with chemotherapy (group B)
Study: 37562004
Drug: OAsIs combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAsIs combination therapy (targeted therapies against CD20, BCL2, and Bruton tyrosine kinase)
Study: 37562063
Drug: Imipenem/cilastatin/relebactam (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin/relebactam (maximum dose of 15 mg/kg imipenem and 15 mg/kg cilastatin, 7.5 mg/kg relebactam)
Study: 37562095
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg BID or 1500 mg BID) combined with platinum-based chemoradiation
Study: 37562095
Drug: Metformin compliance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin compliance ≥70%
Study: 37562641
Drug: BI 1026706
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1026706 100 mg bid
Study: 37562934
Drug: Codesigned complex
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codesigned complex intervention to prevent pressure ulcers, malnutrition, poor oral health and falls
Study: 37563004
Drug: Eliapixant 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eliapixant 125 mg twice daily
Study: 37563240
Drug: Durvalumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab plus tremelimumab combined with mFOLFOX6 chemotherapy
Study: 37563568
Drug: hrBMP4 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: hrBMP4 (0.5 to 18 mg)
Study: 37564370
Drug: Therapeutic SCiP™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic SCiP™ therapy for 8 weeks (G2)
Study: 37564370
Drug: Therapeutic SCiP™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic SCiP™ therapy for another 8 weeks (G2)
Study: 37564370
Drug: Sham stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham stimulation followed by therapeutic SCiP™ therapy for 8 weeks (G1)
Study: 37564370
Drug: Activity-based neurorehabilitation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activity-based neurorehabilitation therapy (ABNT) 2 days/week for both groups
Study: 37565393
Drug: Trial-related blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial-related blood sampling (1.6 ± 0.6 mL/kg)
Study: 37565393
Drug: Clinical blood
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical blood sampling (8.1 ± 5.1 mL/kg)
Study: 37565541
Drug: Lemborexant 10
Normalized name: lemborexant 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemborexant 10 mg oral dose